首页> 中文期刊> 《西南国防医药 》 >伽玛刀联合华蟾素治疗肺腺癌的临床研究

伽玛刀联合华蟾素治疗肺腺癌的临床研究

             

摘要

Objective To explore the clinical efficacy of whole body γ - knife combined with cinobufacin on adenocarcinoma of lung. Methods 48 patients with adenocarcinoma of lung were randomly divided into two groups( n= 24 ). Both combined treatment group and control group received whole body γ - knife for 2 - 3 w at a dose of 25 - 40 Gy around the target, median dose of 35 Gy and fractionated dose of 2.5 - 4.0 Gy once daily for 5 d per week. Those in combined treatment group were additionally injected with cinobufacin for two courses of treatment taking 30 ml once daily for 6 d per week and repeated use for 3 w as a course of treatment. The differences in curative effects and survival time were compared between the two groups after 12 - month follow up. Results The decrease in tumor size, intrahepatic and peritoneal metastatic rate, 12 - month suvival rate, quality of life and serum levels of tumor markers, WBC and liver function in combined treatment group were markedly superior to control group( P < 0.05 ). Conclusion Whole body γ - knife plus cinobufacin is of good clinical efficacy on adenocarcinoma of lung. It can further improve these patients' quality of life and long - term suvival rate.%目的 探讨全身伽玛刀联合华蟾素治疗肺腺癌的临床疗效.方法 48例肺腺癌患者随机分为2组,联合组(24例)接受全身伽玛刀联合华蟾素治疗,对照组(24例)接受单纯伽玛刀治疗,观察两组患者的疗效和生存期差异.结果 治疗后联合组的患者在肿瘤体积变化、肝内及腹腔转移率、1年生存率、肿瘤标志物水平、生活质量及部分实验室结果等临床疗效指标上,均明显优于对照组(P<0.05).结论 全身伽玛刀联合华蟾素治疗肺腺癌有较好的临床疗效,能进一步提高患者的生活质量和远期生存率.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号